| Company Name: | ACADIA Pharmaceuticals, Incorporated | | Ticker Symbol: | ACAD | | | WWW Address: | www.acadia-pharm.com | | CEO: | Dr. Uli Hacksell, Ph.D. | | No. of Employees: | 63 | | Common Issue Type: | CS | | Business Description: | The company is focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.33 |  -0.09 | 1.25 | 1.69 | 1.37 | 1.45 | 1.33 | 250383 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 50.9 | 38.3 | 2.26 | -1.73 | 0.00 | 0.0 | 0.0 | 6.60 - 0.75 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.33 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 50.9 | mil |
| Latest Shares Outstanding | 38.3 | mil |
| Earnings pS (EPS) | -1.73 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 25,238 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 37.2 | mil |
| Float as % of Shares Outstanding | 99.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 202.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 926.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -86.2 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -263.7 | % |
| Current Ratio | 3.7 | |
| Leverage Ratio (Assets/Equity) | 3.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.03 | |
| LT Debt/Total Capital | 1.0 | % |
| Working Capital pS | 1.09 | $ |
| Cash pS | 0.45 | $ |
| Book-Value pS | 0.50 | $ |
| Tangible Book-Value pS | 0.50 | $ |
| Cash Flow pS | -1.28 | $ |
| Free Cash Flow pS | -0.45 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.68 | |
| Price/Tangible Book Ratio | 2.68 | |
| Price/Cash Flow | -1.0 | |
| Price/Free Cash Flow | -2.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -8.3 | 92 | 4,596 | 12,295 |
| 4 Weeks | 1.63 | 1.17 | 1.60 | -16.9 | 82 | 4,763 | 95,262 |
| 13 Weeks | 6.40 | 1.17 | 5.64 | -76.4 | 22 | 22,969 | 1,470,038 |
| 26 Weeks | 6.60 | 1.17 | 1.86 | -28.5 | 58 | 17,106 | 2,172,401 |
| 52 Weeks | 6.60 | 0.75 | 0.86 | 54.7 | 113 | 9,653 | 2,422,832 |
| YTD | 6.60 | 0.75 | - | 47.8 | 122 | 10,557 | 2,375,282 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.39 | 1.43 | 1.63 | 2.46 | 2.06 | 2.26 | 2.37 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -13.44 | 16.8 | -28.15 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -26.24 | NA | -45.72 |
| R&D | 19.67 | NA | 4.13 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 266.0 | 763.5 | -79.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.38 | 0.19 | -0.13 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 79.37 |
| Current Ratio | 5.6 |
| Quick Ratio (Acid Test) | 5.4 |
| Liquidity Ratio (Cash) | 5.44 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 96.9 |
| Working Capital pS | 1.38 |
| Cash-Flow pS | -1.68 |
| Free Cash-Flow pS | -1.75 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -1.09 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 18.1 |
| Total Debt/Equity (Gearing Ratio) | 0.02 |
| LT Debt/Equity | 0.01 |
| LT Debt/Capital Invested | 1.2 |
| LT Debt/Total Liabilities | 3.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.34 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.53 |
| Tobin's Q Ratio | 0.79 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.04 |
| Enterprise Value (EV)/Free Cash Flow | 0.12 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.68 |
| Price/Book Ratio - LTM | 2.68 |
| Price/Cash Flow Ratio | -1.0 |
| Price/Free Cash Flow Ratio - LTM | -2.9 |
| Price/Sales Ratio | 10.27 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.01 |
| Current Liabilities pS | 0.30 |
| Tangible Book Value pS - LTM | 0.50 |
| Book Value pS - LTM | 0.50 |
| Capital Invested pS | 1.40 |
| Cash pS - LTM | 0.45 |
| Cash Flow pS - LTM | -1.28 |
| Free Cash Flow pS - LTM | -0.45 |
| Earnings pS (EPS) | -1.73 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -4,094.03 |
| Free Cash Flow Margin 5YEAR AVG | -1,203.43 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.03 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.03 |
| Return on Capital Invested (ROCI) | -120.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -73.1 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -99.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | -57.6 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 25,238 |
| Net Income per Employee | -1,019,746 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 143.58 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.03 |
| Fixed Assets Turnover | 0.69 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.08 |
| Revenue per $ Plant | 0.76 |
| Revenue per $ Common Equity | 0.03 |
| Revenue per $ Capital Invested | 0.03 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 743.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 178.4 |
| Research & Devlopment (R&D) as % of Revenue | 3569.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 3569.2 |
|
|  
|
| |
 |  |